Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Low Levels of Neutralizing Antibodies Against SARS-CoV-2 KP.3.1.1 and XEC in Serum From Seniors in May 2024.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Wiley Country of Publication: England NLM ID: 101304007 Publication Model: Print Cited Medium: Internet ISSN: 1750-2659 (Electronic) Linking ISSN: 17502640 NLM ISO Abbreviation: Influenza Other Respir Viruses Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Oxford, UK : Wiley, c2007-
    • الموضوع:
      SARS-CoV-2*/immunology ; Antibodies, Neutralizing*/blood ; Antibodies, Neutralizing*/immunology ; Antibodies, Viral*/blood ; Antibodies, Viral*/immunology ; COVID-19*/immunology ; COVID-19*/virology ; COVID-19*/blood; Humans ; Aged ; Aged, 80 and over ; Male ; Female ; COVID-19 Vaccines/immunology ; COVID-19 Vaccines/administration & dosage
    • نبذة مختصرة :
      New immune evasive variants of SARS-CoV-2 may increase infections and hospitalizations in risk groups, such as the elderly. In this study, we evaluated neutralizing antibodies against KP.3.1.1 and XEC, virus variants that were either widely distributed or on the rise globally in the fall of 2024, in sera from a cohort of seniors aged 68-82 years collected in April/May 2024. Neutralizing responses were low against both KP.3.1.1 and XEC, also in XBB.1.5 boosted individuals and people with recent break-through infections, supporting the recommendation of an updated COVID-19 vaccine booster in this age group.
      (© 2025 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)
    • References:
      EBioMedicine. 2024 Oct;108:105317. (PMID: 39260039)
      Lancet Healthy Longev. 2023 May;4(5):e188-e199. (PMID: 37148891)
      Lancet Infect Dis. 2024 Dec;24(12):e732-e733. (PMID: 39522531)
      Euro Surveill. 2023 Sep;28(36):. (PMID: 37676147)
      Lancet Infect Dis. 2024 Oct;24(10):e609. (PMID: 39159637)
      Nat Med. 2024 Oct;30(10):2805-2812. (PMID: 39060660)
      Science. 2022 Jan 07;375(6576):43-50. (PMID: 34812653)
      NPJ Vaccines. 2024 Nov 11;9(1):215. (PMID: 39528468)
      BMJ Med. 2024 Nov 17;3(1):e001074. (PMID: 39902239)
      Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
      Lancet Infect Dis. 2025 Jan;25(1):e6-e7. (PMID: 39586310)
      Influenza Other Respir Viruses. 2024 Nov;18(11):e70009. (PMID: 39523781)
      BMC Infect Dis. 2024 Aug 20;24(1):841. (PMID: 39164637)
      Lancet Reg Health Eur. 2024 Feb 02;38:100855. (PMID: 38476753)
      Influenza Other Respir Viruses. 2023 Jun 02;17(6):e13144. (PMID: 37273461)
    • Grant Information:
      Norwegian Institute of Public Health
    • Contributed Indexing:
      Keywords: KP.3.1.1; SARS‐CoV‐2; XEC; elderly; immunity; neutralizing antibodies
    • الرقم المعرف:
      0 (Antibodies, Neutralizing)
      0 (Antibodies, Viral)
      0 (COVID-19 Vaccines)
    • الموضوع:
      Date Created: 20250515 Date Completed: 20250515 Latest Revision: 20250604
    • الموضوع:
      20250604
    • الرقم المعرف:
      PMC12078752
    • الرقم المعرف:
      10.1111/irv.70102
    • الرقم المعرف:
      40369880